Exercise rescued chronic kidney disease by attenuating cardiac hypertrophy through the cardiotrophin-1 → LIFR/gp 130 → JAK/STAT3 pathway

European Journal of Preventive Cardiology

Volumn 21, Issue 4, 2014, Pages 507-520

  Chen, Kuan Chou ^a   Hsieh, Chiu Lan ^b   Peng, Chiung Chi ^a   Peng, Robert Y ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Cardiac hypertrophy; chronic kidney disease (CKD); doxorubicin

Indexed keywords

CARDIOTROPHIN 1; CD34 ANTIGEN; CREATININE; DOXORUBICIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR RECEPTOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; STAT3 PROTEIN; BIOLOGICAL MARKER; CYTOKINE; IL6ST PROTEIN, RAT; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA; LIFR PROTEIN, RAT; STAT3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DOWN REGULATION; EXERCISE; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; MALE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SWIMMING; TREADMILL EXERCISE; UPREGULATION; ANIMAL; CARDIOMEGALY; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; ENDOTHELIUM CELL; ENZYMOLOGY; HEART MUSCLE CELL; KIDNEY; KINESIOTHERAPY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RUNNING; SPRAGUE DAWLEY RAT; STEM CELL; TIME;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMEGALY; CYTOKINE RECEPTOR GP130; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EXERCISE THERAPY; GLOMERULAR FILTRATION RATE; JANUS KINASES; KIDNEY; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MALE; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; RUNNING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STEM CELLS; SWIMMING; TIME FACTORS;

EID: 84896485319     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312462827     Document Type: Article

References (73)

1. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003 ; 41: 47-55
2. Napoli C, Casamassimi A, Crudele V, et al. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol. 2011 ; 7: 485-497
3. Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease prognosis, risk factors and management. Nephrol Dial Transplant. 2000 ; 15: 58-68
4. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999 ; 56: 2214-2219
5. Miranda Sde P, Macedo RN, Silva Júnior GB, et al. Cardio-renal syndrome: pathophysiology and treatment. Rev Assoc Med Bras. 2009 ; 55: 89-94
6. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999 ; 34: 125-134
7. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classiïcation, and stratiïcation. Am J Kidney Dis. 2002 ; 39: S1 - S266
8. Mangione F, Dal Canton A. Chronic kidney disease epidemic: myth and reality. Intern Emerg Med. 2011 ;: 69-76
9. Tremblay L. Heart attack and chronic kidney disease. New York: About.com, Heart Health Center. Available at: http://heartdisease.about.com/lw/Health- Medicine/Conditions-and-diseases/Heart-Attack-and-Chronic-Kidney-Disease.htm (2008, assessed 5 June 2012).
10. Shastri S, Sarnak MJ. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis. 2010 ; 56: 399-417
11. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J. 2005 ; 26: 11-17
12. El Desoky ES. Drug therapy of heart failure: an immunologic view. Am J Ther. 2011 ; 18: 416-425
13. Prabhu SD, Chandrasekar B, Murray DR, et al. beta-Adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000 ; 101: 2103-2109
14. Dhingra S, Sharma AK, Arora RC, et al. IL-10 attenuates TNF-alpha-induced NF kappaB pathway activation and cardiomyocyte apoptosis. Cardiovasc Res. 2009 ; 82: 59-66
15. Engel D, Peshock R, Armstong RC, et al. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol. 2004 ; 287: H1303 - H1311
16. Haudek SB, Taffet GE, Schneider MD, et al. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 2007 ; 117: 2692-2701
17. Kaur K, Sharma AK, Dhingra S, et al. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol. 2006 ; 41: 1023-1030
18. Kim YS, Morgan MJ, Choksi S, et al. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell. 2007 ; 26: 675-687
19. Kaur J, Dhaunsi G, Turner R. Interleukin-1 and nitric oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells. Med Princ Pract. 2004 ; 13: 26-29
20. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 ; 53: 589-596
21. Damman K, Voors AA, Hillege HL, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail. 2010 ; 12: 974-982
22. Onat D, Jelic S, Schmidt AM, et al. Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. J Appl Physiol. 2007 ; 103: 1873-1878
23. Colombo PC, Banchs JE, Celaj S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005 ; 111: 58-62
24. Jougasaki M. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010 ; 52: 41-76
25. Calabrò P, Limongelli G, Rieglewr LV, et al. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol. 2009 ; 46: 142-148
26. Pemberton CJ, Raudsepp SD, Yandle TG, et al. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005 ; 68: 109-117
27. Lopez B, Gonzalez A, Lasarte JJ, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. J Hypertens. 2005 ; 23: 625-632
28. Cottone S, Nardi E, Mulè G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007 ; 67: 209-216
29. Talwar S, Squire IB, Downie PF, et al. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond). 2000 ; 99: 83-88
30. Jougasaki M. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010 ; 52: 41-76
31. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton). 2011 ; 16: 30-38
32. Peng CC, Chen KC, Lu HY, et al. Treadmill exercise improved adriamycin-induced nephropathy. J Biol Regul Homeost Agents. 2012 ; 26: 15-28
33. Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977 ; 37: 2705-2713
34. Szymanski MK, de Boer RA, Navis GJ, et al. Animal models of cardiorenal syndrome: a review. Heart Fail Rev. 2012 ; 17: 411-420
35. Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 2006; 104: e6-e14.
36. Information; dialysis and renal transplantation. Ottawa, Canada: Canadian Organ Replacement Register ; 2001 :
37. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000 ; 35: S117 - S131
38. Painter P. Exercise in chronic disease: physiological research needed. Exerc Sport Sci Rev. 2008 ; 36: 83-90
39. Bloomfield SA and Coyle EF. Bed rest, detraining, and retention of training-induced adaptations: a review. In: American Collage of Sports Medicine (eds) Resource manual for guidelines for exercise testing and prescription. 2nd edn. Philadelphia: Lea and Febiger, 1993. pp. 115-128.
40. Miller TD, Balady GJ, Fletcher GF. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med. 1997 ; 19: 220-229
41. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med. 2006 ; 354: 2473-2483
42. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. New York: NKF. Available at: www.kidney.org/professionals/kdoqi/guidelines-ckd/toc. htm (2002, consulted August 2010).
43. Liang Y, Li YJ. Expression of JAKs/STATs pathway molecules in rat model of rapid focal segmental glomerulosclerosis. Pediatr Nephrol. 2009 ; 24: 1667-1671
44. Adams GR, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. Am J Physiol Renal Physiol. 2006 ; 290: F753 - F761
45. Hirschberg R, Kopple JD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest. 1989 ; 83: 326-330
46. Husain K. Physical conditioning modulates rat cardiac vascular endothelial growth factor gene expression in nitric oxide-deficient hypertension. Biochem Biophys Res Commun. 2004 ; 320: 1169-1174
47. Barouch LA, Cappola TP, Harrison RW, et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol. 2003 ; 35: 637-644
48. Varghese P, Harrison RW, Lofthouse RA, et al. beta(3)-Adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest. 2000 ; 106: 697-703
49. Murad F. The role of nitric oxide in modulating guanylyl cyclase. Neurotransmission. 1994 ; 10: 1-4
50. d'Ischia M, Palumbo A, Buzzo F. Interactions of nitric oxide with lipid peroxidation products under aerobic conditions: inhibitory effects on the formation of malondialdehyde and related thiobarbituric acid-reactive substances. Nitric Oxide. 2000 ; 4: 4-14
51. Peng CC, Chen KC, Hsieh CL, et al. Swimming exercise prevents fibrogenesis in chronic kidney disease by inhibiting the myofibroblast transdifferentiation. PLoS One. 2012 ; 7 (6). e37388 - e37388
52. Pennica D, King KL, Shaw KJ, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA. 1995 ; 92: 1142-1146
53. Stephanou A, Brar B, Heads R, et al. Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol. 1998 ; 30: 849-855
54. Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996 ; 271: 9535-9545
55. Freed DH, Chilton L, Li Y, et al. Role of myosin light chain kinase in cardiotrophin-1-induced cardiac myofibroblast cell migration. Am J Physiol Heart Circ Physiol. 2011 ; 301: H514 - H522
56. Zolk O, Engmann S, Münzel F, et al. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab. 2005 ; 288: E1214 - E1221
57. Tsutamoto T, Asai S, Tanaka T, et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail. 2007 ; 9: 1032-1037
58. Adams GR, Zhan CD, Haddad F, et al. Voluntary exercise during chronic renal failure in rats. Med Sci Sports Exerc. 2005 ; 37: 557-562
59. Freed DH, Cunnington RH, Dangerfield AL, et al. Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infracted heart. Cardiovasc Res. 2005 ; 65: 782-792
60. Matsui H, Fujio Y, Kunisada K, et al. Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in murine cardiac myocytes. Res Commun Mol Pathol Pharmacol. 1996 ; 93: 149-162
61. Kunisada K, Tone E, Fujio Y, et al. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation. 1998 ; 98: 346-352
62. Latchman DS. Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther. 2000 ; 85: 29-37
63. Wagner M, Siddiqui MA. Signaling networks regulating cardiac myocyte survival and death. Curr Opin Investig Drugs. 2009 ; 10: 928-937
64. Kunisada K, Negoro S, Tone E, et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA. 2000 ; 97: 315-319
65. Takahashi N, Saito Y, Kuwahara K, et al. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol. 2005 ; 38: 185-192
66. McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA. 2003 ; 100: 12355-12360
67. DeBosch B, Treskov I, Lupu TS, et al. Akt1 is required for physiological cardiac growth. Circulation. 2006 ; 113: 2097-2104
68. Rakusan R The stressed heart. Legato MJ, ed. Boston, Dordrecht, and Lancaster: Martinus Nijhoff Publ ; 1987: 107-123.
69. Rakobowchuk M, Harris E, Taylor A, et al. Heavy and moderate interval exercise training alters low-flow-mediated constriction but does not increase circulating progenitor cells in healthy humans. Exp Physiol. 2012 ; 97: 375-385
70. Luk TH, Dai YL, Siu CW, et al. Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial. Eur J Cardiovasc Prev Rehabil. 2012 ; 19: 830-839
71. Frenzel H, Schwartzkopff B, Höltermann W, et al. Regression of cardiac hypertrophy: morphometric and biochemical studies in rat heart after swimming training. J Mol Cell Cardiol. 1988 ; 20: 737-751
72. Van Craenenbroeck EM, Hoymans VY, Beckers PJ, et al. Exercise training improves function of circulating angiogenic cells in patients with chronic heart failure. Basic Res Cardiol. 2010 ; 105: 665-676
73. Nikol S, Kuhlmann M. Mobilization of stem cells in cardiovascular disease. Improvement of vascularization, cardiac function and arrhythmias. Med Klin (Munich). 2006 ; 101: 190-192